Pfizer reported second-quarter revenue of $15.03 billion and raised the midpoint of its full-year revenue guidance on Tuesday, driven by stronger-than-expected performance from recently launched and acquired products.
The company now expects full-year 2026 revenue of $60.5 billion to $62.5 billion, up from a previous range of $59.5 billion to $62.5 billion
On an adjusted basis, earnings reached 77 cents per share, clearing the 68-cent consensus estimate, according to CNBC. On a reported basis, Pfizer posted a loss per share of $0.04, reflecting $4.3 billion in non-cash intangible asset impairments. The guidance update incorporates roughly $1.5 billion in upside from non-COVID products, though that gain was tempered by a reduction in the company’s forecast for COVID-19 treatments, which Pfizer now pegs at roughly $4 billion for the year, compared with a prior expectation of around $5 billion.
The company left its full-year adjusted earnings outlook unchanged at $2.80 to $3.00 per share. Revenue growth was led by several products. Eliquis rose 19% operationally, driven by higher net prices in the U.S. and stronger global demand.